Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Targeting interleukin-4 to the arthritic joint

Spieler, Valerie, Ludwig, Marie-Gabrielle, Dawson King, Janet, Tigani, Bruno, Littlewood-Evans, Amanda, Raschig, Martina , ter Mors, Björn, Müller, Thomas, Meinel, Lorenz and Lühmann, Tessa (2020) Targeting interleukin-4 to the arthritic joint. Journal of controlled release, 326. pp. 172-180. ISSN 1873-4995


Anti-inflammatory cytokines are a promising class of therapeutics for treatment of rheumatoid arthritis (RA) but their use is currently limited by a rapid clearance and systemic toxicity. Interleukin-4 is a small molecular weight cytokine with potential for RA therapy. To increase its pharmacokinetic features, we engineered a murine IL4 conjugate by incorporating an unnatural amino acid through genetic codon expansion to which PEG-folate as targeting moiety and PEG as control were site-specifically bound. Both IL4 conjugates retained bioactivity and induced primary murine macrophage polarization into an alternatively activated (M2) related phenotype. The PEGylated conjugates had a terminal half-life of about four hours in healthy mice. We showed that both conjugates successfully accumulated into arthritic joints in an antigen-induced arthritis (AIA) mouse model as assessed by non-invasive fluorescence imaging. The modular nature of the IL4 conjugate chemistry presented herein facilitates easy adaption of PEG chain length and targeting moieties to further improvement of half-life and targeting function for future efficacy studies.

Item Type: Article
Date Deposited: 05 Sep 2020 00:45
Last Modified: 05 Sep 2020 14:07


Email Alerts

Register with OAK to receive email alerts for saved searches.